Is BMS 354825 Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use BMS 354825? Is BMS 354825 safe for nursing mother and child? Does BMS 354825 extracts into breast milk? Does BMS 354825 has any long term or short term side effects on infants? Can BMS 354825 influence milk supply or can BMS 354825 decrease milk supply in lactating mothers?

• DrLact safety Score for BMS 354825 is 5 out of 8 which is considered Unsafe as per our analyses.
• A safety Score of 5 indicates that usage of BMS 354825 may cause serious side effects in breastfed baby.
• Our study of different scientific research indicates that BMS 354825 may cause moderate to high side effects or may affect milk supply in lactating mother.
• Our suggestion is to use safer alternate options rather than using BMS 354825 .
• It is recommended to evaluate the advantage of not breastfeeding while using BMS 354825 Vs not using BMS 354825 And continue breastfeeding.
• While using BMS 354825 Its must to monitor child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
• Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Inhibitor of BCR-ABL and SRC tyrosine kinase that is used for treatment of Chronic Myeloid Leukemia with positive Philadelphia chromosome. At latest update, relevant published data on excretion into breast milk were not found. Because of high serum protein-binding capacity, excretion into breast milk in significant amount is seemingly unlikely. If continuation of safely breastfeeding is desired without assuming high risk for potentially severe side-effects, elimination of total burden of drug should be kept. For this to happen, breastfeeding should be stopped for 10 half-lives (T ½). It means wait two and a half days after last dose before resuming breastfeeding. Meanwhile, frequent pump-and-dump is recommended for maintenance of milk production.

Although one breastfed infants apparently experienced no adverse effects during maternal use of BMS 354825, no long-term data are available. Because BMS 354825 and its metabolite are more than 90% bound to plasma proteins, the amounts in milk are likely to be low. However, there is little published experience with BMS 354825 during breastfeeding, and an alternate drug may be preferred, especially while nursing a newborn or preterm infant. The manufacturer recommends that breastfeeding be discontinued during BMS 354825 therapy and for 2 weeks after the last dose.

A woman with chronic myeloid leukemia received BMS 354825 100 mg daily throughout pregnancy and continuing postpartum, apparently while breastfeeding her infant (extent not stated). No adverse reactions were reported in her infant.[1]